These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 16114291)

  • 1. [The polypill: not an effective strategy for reduction of cardiovascular disease].
    Westerweel PE; van Wijk JP; Verhaar MC
    Ned Tijdschr Geneeskd; 2005 Jul; 149(31):1741. PubMed ID: 16114291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The polypill: optimal strategy for reduction of cardiovascular disease].
    Nathoe HM; Doevendans PA
    Ned Tijdschr Geneeskd; 2005 Jul; 149(31):1740. PubMed ID: 16114290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Polypill in the prevention of cardiovascular disease.
    Wald DS; Wald NJ
    Prev Med; 2011 Jan; 52(1):16-7. PubMed ID: 21130112
    [No Abstract]   [Full Text] [Related]  

  • 4. [Cardiovascular disease in those aged 55 years and over controlled with a combined pill against 4 risk factors: some brief comments].
    Rabelink TJ
    Ned Tijdschr Geneeskd; 2003 Aug; 147(32):1537-8. PubMed ID: 12942841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospects and possible pitfalls of a preventive Polypill: confessions of a health promotion convert.
    Green LW
    Eur J Clin Nutr; 2005 Aug; 59 Suppl 1():S4-8; discussion S9. PubMed ID: 16052194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting the impact of polypill use in a metabolic syndrome population: an effectiveness and cost-effectiveness analysis.
    Zomer E; Owen A; Magliano DJ; Ademi Z; Reid CM; Liew D
    Am J Cardiovasc Drugs; 2013 Apr; 13(2):121-8. PubMed ID: 23532687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polypill in cardiovascular disease: has it's time come?
    Kuppuswamy V; Choo WK; Gupta S
    Indian Heart J; 2009; 61(4):322-7. PubMed ID: 20635733
    [No Abstract]   [Full Text] [Related]  

  • 8. Polypill: Can its Potential Enhancement of Efficacy Trigger New Interest?
    Chao J; Bansilal S
    Glob Heart; 2016 Dec; 11(4):469-472. PubMed ID: 27938845
    [No Abstract]   [Full Text] [Related]  

  • 9. A single pill for prevention?
    Harv Heart Lett; 2009 Jul; 19(11):6. PubMed ID: 19927382
    [No Abstract]   [Full Text] [Related]  

  • 10. "Polypill-aspostatinoprilololazide folate"--coprescription for at the risk Asian Indian in chronic non communicable diseases.
    Joshi SR
    J Assoc Physicians India; 2005 Mar; 53():175-8. PubMed ID: 15926597
    [No Abstract]   [Full Text] [Related]  

  • 11. [The Polypill: between myths and reality in the treatment of type 2 diabetes mellitus].
    Ruiz J; Egli M
    Rev Med Suisse; 2006 May; 2(68):1480-2, 1484-5. PubMed ID: 16783994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefits, challenges, and registerability of the polypill.
    Sleight P; Pouleur H; Zannad F
    Eur Heart J; 2006 Jul; 27(14):1651-6. PubMed ID: 16603580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The polypill to prevent cardiovascular disease: physicians' perspectives.
    Viera AJ
    Curr Opin Cardiol; 2011 Sep; 26(5):438-42. PubMed ID: 21730826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 2016 Joint European Prevention Guidelines and the uses of polypills: Time to update the evidence.
    Webster R; Grobbee D; Rodgers A
    Eur J Prev Cardiol; 2020 Mar; 27(4):437-440. PubMed ID: 31446790
    [No Abstract]   [Full Text] [Related]  

  • 15. The evening versus morning polypill utilization study: the TEMPUS rationale and design.
    Lafeber M; Grobbee DE; Bots ML; Thom S; Webster R; Rodgers A; Visseren FL; Spiering W
    Eur J Prev Cardiol; 2014 Apr; 21(4):425-33. PubMed ID: 23382539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
    Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A;
    Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prevention of cardiovascular diseases using a combined pharmacological approach: is there any place for a "polypill"?].
    Scheen AJ; Lefèbvre PJ; Kulbertus H
    Rev Med Liege; 2003 Sep; 58(9):527-33. PubMed ID: 14626644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
    Lafeber M; Spiering W; Visseren FL; Grobbee DE; Bots ML; Stanton A; Patel A; Prabhakaran D; Webster R; Thom S; Rodgers A;
    Eur J Prev Cardiol; 2017 Jun; 24(9):951-961. PubMed ID: 28436727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The concept of the polypill in the prevention of cardiovascular disease.
    Wiley B; Fuster V
    Ann Glob Health; 2014; 80(1):24-34. PubMed ID: 24751562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Requirement of pharmacological treatment for primary prevention of cardiovascular disease in asymptomatic office-executives in north-India.
    Kasliwal RR; Bansal M; Mehrotra R; Agrawal V; Shrivastava S
    Indian Heart J; 2010; 62(4):324-9. PubMed ID: 21280473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.